Therapy-related myelodysplasia and leukemia occur infrequently following VP-16 priming and autotransplantation without total body irradiation

E. Copelan, S. Hoshaw-Woodard, P. Elder, S. Penza, S. Farag, G. Marcucci, T. Lin, S. Ezzone, M. D. Scholl, T. Bechtel, S. Lemeshow, B. Avalos

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

The use of VP-16 for stem cell mobilization has been cited as a significant risk factor for the development of therapy-related myelodysplasia/leukemia (tMDS/tAML) following autologous transplantation. The present study analyzed a large cohort of patients who underwent autotransplantation following stem cell mobilization with VP-16 and radiation-free preparation in order to determine the risk of tMDS/tAML. The estimated incidence of 9.9% at 7 years suggests that in the absence of TBI, VP-16 priming is not associated with an increased incidence of tMDS/tAML.

Original languageEnglish (US)
Pages (from-to)85-87
Number of pages3
JournalBone Marrow Transplantation
Volume34
Issue number1
DOIs
StatePublished - Jul 1 2004

    Fingerprint

Keywords

  • Autotransplantation
  • Secondary AML
  • VP-16

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Copelan, E., Hoshaw-Woodard, S., Elder, P., Penza, S., Farag, S., Marcucci, G., Lin, T., Ezzone, S., Scholl, M. D., Bechtel, T., Lemeshow, S., & Avalos, B. (2004). Therapy-related myelodysplasia and leukemia occur infrequently following VP-16 priming and autotransplantation without total body irradiation. Bone Marrow Transplantation, 34(1), 85-87. https://doi.org/10.1038/sj.bmt.1704532